Treatment Strategies for Relapsed/Refractory AML Patients

Author(s):

Thomas W. LeBlanc, MD, MA, MHS, FAAHPM, FASCO ,James Blachly, MD

Panelists discuss how the latest NCCN guidelines for relapsed/refractory acute monocytic leukemia (R/R AML) outline targeted therapy options outside clinical trials, and explore treatment approaches based on patient fitness, actionable biomarkers, and prior therapies, highlighting the impact of first remission duration and genetic abnormalities on treatment sequencing.

Now Viewing

EP: 1.Treatment Strategies for Relapsed/Refractory AML Patients

EP: 2.Treatment Goals and Unmet Needs in R/R AML

EP: 3.Navigating Challenges in Second- and Third-Line AML Therapy

EP: 4.Revumenib’s FDA Approval and Clinical Implications

EP: 5.Efficacy and Potential of Revumenib in KMT2A-Translocated Leukemia

EP: 6.Adverse Event Management and Patient Safety With Revumenib

EP: 7.MRD Testing and the Role of Revumenib in Treatment Response

EP: 8.Integrating Revumenib Into Current R/R AML Treatment Paradigms

EP: 9.Genetic Testing and Molecular Profiling in AML

EP: 10.Emerging Combination Strategies and Preclinical Findings

Video content above is prompted by the following:

Briefly review targeted therapy options outside of a clinical trial for relapsed/refractory AML according to the latest NCCN guidelines.
What is your treatment approach for those R/R patients who are fit enough for an aggressive chemotherapy-based regimen, but also have an actionable biomarker?

How does length of first remission play into that decision-making and/or whether they have already gone through allo-HSCT?

On the other hand, for those R/R AML patients who received a previous “lower-intensity therapy” such as venetoclax-based therapy or IDH1-based therapy, what is your typical treatment sequencing?